Managing finances with the uncertainty of Medicare reimbursement rates took the top worry among 1,252 medical practice professionals participating in a survey from Medical Group Management Association-American College of Medical Practice Executives (MGMA-ACMPE) on their daily struggles.

Nearly 90 percent of pediatric patients with favorable-risk Hodgkin lymphoma and a complete early response to chemotherapy who bypassed radiation therapy (RT) achieved two-year event-free survival, according to a study published June 27 in the Journal of the American Medical Association.

Researchers from VTT Technical Research Centre of Finland in collaboration with the University of Eastern Finland have reportedly discovered a serum biochemical signature which predicts progression to Alzheimers disease before the first symptoms of the disease occur. VTT and GE Healthcare have formed a collaboration to validate this biomarker in a large patient cohort as well as to discover novel biomarker candidates.

The detection of kidney stones using extremely low-dose CT is more difficult in obese patients, but new research has shown that the sensitivity and specificity for the detection of ureteral calculi on CT is decreased for underweight patients as well, according to a study published in the July issue of the Journal of Urology.

Regardless of how the U.S. Supreme Court rules on the Patient Protection and Affordable Care Act (PPACA), the demand for healthcare workers will grow at double the rate of the national economy over the next eight years and 5.6 million new jobs will be created, according to a study from the Georgetown University Center on Education and the Workforce.

GE is pouring $7.5 million into an Australian company, Nanosonics, to push along the latters development and distribution of a disinfecting system for ultrasound transducers called Trophon EPR.

18F-FDG PET/CT can aid the noninvasive preoperative determination of malignancy and may be helpful in detecting metastases of malignant cardiac tumors, according to a small study published in the June issue of the Journal of Nuclear Medicine.

The FDA has issued a complete response letter regarding Janssen Research & Development's supplemental New Drug Application for rivaroxaban (Xarelto) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS). Janssen said it is evaluating the complete response letter and will respond to the agency's questions.